Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.82 |
| ▸ | ADRB1 | P08588 | 14/20 | 0.82 |
| ▸ | ADRB3 | P13945 | 12/20 | 0.82 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | DRD1 | P21728 | 2/20 | 0.60 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843365 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL13708458 | 0.94 | ADRB2 (0.73) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL13589488 | 0.91 | ADRB2 (0.80) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL13708457 | 0.90 | ADRB2 (0.67) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL29798936 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL29390087 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL335742 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL246986 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| SCHEMBL3196487 | 0.90 | ADRB2 (0.66) | ADRB2ADRB1ADRB3DRD2DRD1 | |
| Hydrochloric Acid SCHEMBL4385888 | 0.90 | ADRB2 (0.98) | ADRB2ADRB1ADRB3DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227547-A1 | Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| EP-1893580-A1 | NOVEL SALT FORM OF A ß2 -ADRENERGIC AGONIST QUINOLIN-2-ONE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006133942-A1 | NOVEL SALT FORM OF A β2 -ADRENERGIC AGONIST QUINOLIN-2-ONE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227547-A1 | Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative | ADRB2, ADRA2B, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.